Alport Syndrome Pipeline and Market Outlook: Addressing Unmet Clinical Needs
Here’s the honest state of play: the alport syndrome market has spent decades as a quiet, supportive-care category with almost no dedicated drugs. That’s about to flip. From an estimated USD 27 million across the US, EU4, UK, and Japan in 2025, the market is on track to hit close to USD 1,900 million by…
